MCRB — Seres Therapeutics Share News
0.000.00%
Last trade - 00:00- $20.78m
- $5.18m
- $0.79m
CEO structure
U.S. RESEARCH ROUNDUP- Autozone, Pfizer, Valley National Bancorp
Brief: Seres Therapeutics Announces Further Constructive Feedback from FDA on SER-155 Phase 2 Study Protocol and Implements Cost Reduction Actions to Extend Cash Runway
Factbox: What plans have major automakers announced at the Munich auto show?
Seres Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Seres Therapeutics QTRLY Loss Per Share $2.27
Seres Therapeutics Inc expected to post a loss of $2.49 a share - Earnings Preview
Seres Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Seres Therapeutics Inc Qtrly EPS $3.76
Seres Therapeutics Inc expected to post a loss of 54 cents a share - Earnings Preview
Seres Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary
Brief: Seres Therapeutics FY EPS USD 0
Seres Therapeutics Inc expected to post a loss of 20 cents a share - Earnings Preview
Seres Therapeutics Inc expected to post a loss of 20 cents a share - Earnings Preview
Seres Therapeutics Inc expected to post a loss of 20 cents a share - Earnings Preview
Brief: Seres Therapeutics Announces Receipt of Expected $50 Million Installment Payment Related to VOWST Sale
U.S. STOCKS ON THE MOVE-Apollo, Hershey, RH
U.S. STOCKS ON THE MOVE-Warner Bros, Seres Therapeutics, Enterprise Bancorp
Seres Therapeutics rises on 'breakthrough therapy' tag for blood infection treatment